• Agios Pharmaceuticals Inc., of Cambridge, Mass., said a recent publication highlighted the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo.
To continue reading subscribe now to BioWorld Today
